Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
Adult
Aged
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ epidemiology
Canada
/ epidemiology
Cohort Studies
Female
Humans
Immunity, Humoral
/ immunology
Immunization, Passive
/ methods
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Immunoglobulin M
/ blood
Male
Middle Aged
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Young Adult
COVID-19 Serotherapy
COVID-19
IgA
IgG
IgM
SARS-CoV-2
convalescent plasma
neutralization
spike glycoprotein
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
02 03 2021
02 03 2021
Historique:
received:
19
10
2020
revised:
05
01
2021
accepted:
04
02
2021
pubmed:
18
2
2021
medline:
16
3
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from patients with COVID-19 decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this study, we select plasma from a cohort of convalescent patients with COVID-19 and selectively deplete immunoglobulin A, M, or G before testing the remaining neutralizing capacity of the depleted plasma. We find that depletion of immunoglobulin M is associated with the most substantial loss of virus neutralization, followed by immunoglobulin G. This observation may help design efficient antibody-based COVID-19 therapies and may also explain the increased susceptibility to SARS-CoV-2 of autoimmune patients receiving therapies that impair the production of immunoglobulin M (IgM).
Identifiants
pubmed: 33596407
pii: S2211-1247(21)00104-2
doi: 10.1016/j.celrep.2021.108790
pmc: PMC7874916
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108790Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
Ann Rheum Dis. 2021 May;80(5):e67
pubmed: 32591357
Malar J. 2008 Jul 14;7:129
pubmed: 18625058
Clin Immunol. 2009 Oct;133(1):52-60
pubmed: 19604724
EMBO J. 1997 Feb 17;16(4):695-705
pubmed: 9049299
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Mol Immunol. 2007 Mar;44(8):1854-63
pubmed: 17097144
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Exp Med. 2020 Mar 2;217(3):
pubmed: 31891367
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Transfusion. 2021 May;61(5):1377-1382
pubmed: 33604922
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Semin Arthritis Rheum. 2020 Aug;50(4):680-686
pubmed: 32512263
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Mult Scler Relat Disord. 2020 Jul;42:102192
pubmed: 32570202
Ann Rheum Dis. 2021 Jan;80(1):e10
pubmed: 32312768
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Autoimmun Rev. 2020 Mar;19(3):102466
pubmed: 31917267
Arthritis Rheum. 2008 Jan;58(1):5-14
pubmed: 18163518
J Infect Dis. 2021 Sep 17;224(6):983-988
pubmed: 33693749
PLoS One. 2021 Jan 28;16(1):e0244855
pubmed: 33507994
Mult Scler Relat Disord. 2020 Aug;43:102195
pubmed: 32460086